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Background: Breast cancer is the most common malignancy in women i  Nigeria. Women 
previously treated for ipsilateral breast cancer have increased risk of developing contalateral 
breast cancer (CBC), the chance of which increases with longer period of survival and is 
associated with worse prognosis. Reports from Nigeria are few on this.The aim of this study was 
to assess the prevalence, predisposition, presentation, and outcome of management of bilateral 
breast cancer (BBC) in a population, South-western Nigeria. 
Methods: A review of bio-data of all patients with BBC seen in LTH, Osogbo, Nigeria between 
2001 and 2008 was done. Age, parity, age at menarche and first child birth, family history, 
duration of symptoms, tumour characteristics and exposure to cigarette, oral contraceptive pills 
(O.C Pills) and outcome of treatment were also assessed. 
 Results: BBC constituted 4.6% of the 256 breast cancer patients. Eight (73%) were 
metachronous and 91% were infiltrating ductal carcinoma. Patients’ mean age, mean age at 
menarche and first child birth were 39, 14.5+3 and 22.5yrs respectively. Mean parity was 3.5 
child birth, 91% were premenopausal and all have menstruated for 12-31yrs. None had positive 
family history while only 1 and 3 had insignificant exposure to cigarette and O.C pills 
respectively. The mean interval between the 2 onsets was 18mths (0-68mths). 91% of all 
tumours were advance, while 81% of the first tumours were on the right. Mean duration before 
presentation for the first and second tumours were 261 and 111days respectively. One patient 
has survived for 2 years thus far. 
Conclusion: The incidence of BBC was 4.26%. Most patients were young and premenopausal 
with mostly infiltrating ductal carcinoma (NOS) and presenting with late stage disease, hence 





Breast cancer is the most common female malignancy in Nigeria1. A woman with unilateral breast 
cancer is known to have increased risk of developing contralateral breast cancer (CBC) 2. This 
increases the agony brought about by the disease, more side effects from the ablative surgical 
treatment, adjuvant chemotherapy, radiotherapy all leading to poor prognosis3. 
 
Breast cancer incidence though known to be less in the black Africans appears to be on the increase 
from clinical and also laboratory experiences 4,5,6,7. The incidence of bilateral breast cancer (BBC) has 
been reported to be 2.4% (Ilorin), 2% (Benin), 2.2% (Ife), 4 % ( Lagos) all in Nigeria4,8,9,10, while 
higher incidences of between 3.3% and 9.6% has been reported among the Caucasians 3,11-14.Breast 
cancer is known to occur more in younger and premenopausal women among the blacks, and  usually 
with more aggressive lesion. A long post survival period may give a high propensity for developing 
metachronous CBC. This retrospective study is therefore aimed at highlighting the incidence, biodata, 
clinical features, histology, possible predisposing factors and outcome of treatment of patients with 
BBC in a Nigerian population. 
 
Patients and Methods 
 
The case files of all patients who have had cancer involving the two breasts during an 8 year period 
(2001-2008) in LAUTECH Teaching Hospital, a 300 bed hospital in Osogbo, South western Nigeria 
were retrieved. Bio-data, age, sex, age at menarche and first child birth, parity in addition to family 
history of breast or any other cancers, use of O.C pills or menopausal hormone and social habits like 
smoking, alcohol ingestion were extracted. The tumour locations, disease stage, histology, treatment 
given with outcome were also retrieved. Patients who developed primary contralateral breast cancer  
 




(CBC) within 6 months of onset of the initial cancer were termed synchronous. The period between 




Eleven (4.26%) out of 256 breast cancer patients seen during the study period had bilateral breast 
cancers. All were females with age ranging from 27- to 50 yrs with a mean of 39.1 years. The mean 
age at menarche and first child birth were 14.5 and 22.5 years respectively (Table 1). The mean parity 
was 3.5 child births; one was nultiparous at the age of 45yrs while 3 were grand multips having 
between 6-8 children. All were premenopausal except one in the peri-menopausal period. They have 
all menstruated for between 12-31years. None has family history of breast or any other cancer, only 
one patient smoked and three patients took oral contraceptive pills for period varying from 2-4 years 
(Table 1).  
 
The duration before presentation of the initial tumour was between 2 months and 1 year  with a mean 
of  261days; 45%presented within 6months as against 81% for the contalateral lesion. The mean 
duration of symptom for CBC was 111days. The interval between the first and second tumour onset 
ranged between 0 and 68 months with a mean of 18months. In only 3 patients  was the interval less 
than 6months (synchronous) (Table 2). Tumour locations were symmetrical in 5 of the 11 cases (50% 
of metachronous and 33% of synchronous). Nine of the first lesions were on the right, one each of the 
patient with first left lesion had synchronous and metachronous contalateral lesion. 
 
 



























































































1 OB 35 13 35 2 2 1 16 - - LTFP 
2 OS 36 14 20 8 6 6 18 - + LTFP 
3 FF 50 18 21 6 11 3.7 24 - - DEA
D 
4 AJ* 45 18 / 0 6 2 2 - - DEA
D 
5 BO 44 13 22 6 12 8 20 - - LTFP 
6 SA 34 13 28 2 12 1 20 + - DEA
D 
7 OA 45 14 22 4 10 1 68 - + DEA
D 
8 AO 40 15 24 4 18 6 12 - + DEA
D 
9 OO 30 15 28 2 15 9 6 - - DEA
D 
10 AK 44 12 25 3 2 1 13 - - ALIV
E 
11 UK 27 15 23 2 2 2 0 - - DEA
D 






18.09    
 KEY:   O.C =oral contraceptive,   LTFP= Lost to follow-up.   -=No,   += Yes,   * = Nuliparous  
 



















Tumour Location    
(Quadrants) 
Disease  Stage          
(Manchester 
Class. )                   
    Histology 

















1 OB R L UOQ UOQ 3B 4 IDC IDC 
2 OS R L CENT CENT 3B 3B IDC IDC 
3 FF R L UIQ CENT 4 3A IDC IDC 
4 AJ L R UOQ CENT 4 3B IDC IDC 
5 BO L R UOQ CENT 3B 4 IDC IDC 
6 SA R L UOQ UIQ 3B 4 IDC IDC 
7 OA R L CENT UOQ 3A 3A IDC IDC 
8 AO R L CENT CENT 4 4 IDC IDC 
9 O R L UIQ UOQ 3B 3A IDC IDC 
10 AK R L UOQ UOQ 2 2 IDC IDC 
11 UK R L CENT CENT 3A 3A LYMPH LYMP
H 
KEY: R=Right, L=Left, IDC=Infiltrating Ductal Carcinoma(NOS), LYNPH = lymphoma 
 
Five and 2 of the first tumours were located in the outer and inner quadrants respectively while 4 were 
central. Six (55%) of the contalateral tumours were central while 4 were in the outer quadrant. 
Seventy-five percent of the central first lesion had centrally located contalateral lesion. (Table 2). 
 
All except one had either Manchester stage III or IV in both breasts. All were diagnosed to be 
infiltrating ductal carcinoma (IDC, NOS) except the youngest (27 yr old) with generalized Burkitt 
lymphoma involving both breasts. (Table 2) 
      
All patients with IDC had neo-adjuvant cytotoxic chemotherapy using cyclophosphamide and 
Adriamycin based regime (CAMF). The two patients with synchronous lesions were offered 
simultaneous bilateral mastectomy. The others had simple or modified radical or radical mastectomy 
at each presentation. Tamoxifen at the dose of 20mg daily was given to all while the care lasts. Three 
of them had radiotherapy for additional loco-regional control, two of these developed complications 
including pleuritis, severe pleural effusion and pulmonary fibrosis. The patient with Burkitt 
lymphoma was managed medically using cycles of cytotoxic drugs (CMVP) along with the clinical 
haematologists. Seven of the patients died and three were lost to follow-up within the first year of 
treatment of the contalateral breast lesion. Only one patient is still living 2 years after diagnosis of 




Incidences of breast cancer in women are on the increase worldwide in the recent years 4,7. More cases 
of BBC should be expected, especially in areas where large percentage of breast cancer patients are 
found in the pre- and perimenopausal period.The younger age at presentation provide for higher risk 
of developing contalateral primary breast cancer (CPBC) after surviving the initial lesion. The poor 
survival pattern in the developing world has been attributed to various social, environmental15, in 
addition to some biological factors8. 
 
The incidence of 4.26% found in this study is a bit higher than reported values from other centers in 
Nigeria but lower than reported cases among Caucasians. Poor survival rate and high rate of loss to 
 




follow-up in addition to some social beliefs may partly explain this. Only 27% of cases were 
synchronous, this is in keeping with findings from other centers11-13,16. However the mean age of 
39.1years in BBC patients is significantly lower than 474 and 4816 years reported for all breast cancer 
patients in nearby teaching hospitals, thus supporting the fact that the former are usually younger. 
The mean age at menarche and the age at first child birth of these patients are all similar to that of 
other females with unilateral breast cancer in this environment and comparable with that of women 
population in the locality. Age at menarche, age at first child birth and duration of breast feeding has 
been implicated by some authors as possible predisposing factors to breast cancer17. It has also been 
postulated that carrying a full term pregnancy on or before 18 years is protective against breast 
cancer18. However many studies in Nigeria including that by Ihekwaba FN19 who assessed the risk 
factors in 1946 breast cancer patients could not demonstrate these to be significant predisposing 
factors.  
 
Parity does not appear to offer significant protection against developing first or second primary breast 
cancer in Nigeria, as only one of the patients in this series was nuliparous and three were 
grandmultips. This is in keeping with other reports from within and outside Nigeria 20-23 and in 
contrast to report by George GF from Baltimore (USA) 24. I n the same vein, none of our patients with 
BBC had positive history as against earlier studies in Caucasians in which family history was found to 
be a significant predisposing factor 12,24. Transfer genetically through the Breast cancer related antigen 
(BRCA) I and II as autosomal dominant trait has been proved and this may account for between 50 
and 70% of highly penetrant hereditary breast cancer2. The strength of family history (genetic 
transfer) as a risk factor for unilateral and BBC still need further evaluation among indigenous black 
African women in view of heterogeneity of breast cancer aetiology across regions. However it will be 
difficult to estimate the significance of unknown family history.  
 
The short mean duration of symptoms before the second presentation could be due to awareness from 
their previous experience though this appears to have no effect 0n disease stage of CBC. Mertins 
et.al25 among others reported that subsequent tumours are usually of smaller size and stage, though 
initial tumour size and stage is strongly associated with CPBC size and stage. Aggressive follow-up 
care of the initial tumour including screening of contalateral breast will lead to early detection thus 
smaller size and stage of the subsequent cancers. 
 
The mean interval between cancers of 18months (0-68months) is rather short compared with 
117months reported by Golgas14 or 144months by George GFet.al24, though most are also young and 
premenopausal but with positive family history. Short interval, age, large second tumour size, higher 
number of positive lymph nodes of first and second cancers are factors that decrease the disease 
specific survival in patients with BBC3,26. Skowronek J et.al 27 reported 0 and 73.9% 5-year survival 
in patients with interval period < 2years and > 5years in Poland. In addition, lympho-vascular 
invasion, nuclear grade, histology and hormone receptor status are also related with overall survival28.  
Primary breast cancers are more common on the right4 and 81% of first primary lesions here are found 
on the right. CBC lesions are noted to be commonly located centrally while upper outer quadrant 
lesions are commoner overall; the significance of the former is unknown. 
 
Late presentation with breast cancer is common in the developing world 15,19,23,29, low level of 
awareness30, poverty and fair of mastectomy31 among others could account for this. Presentations of 
CBC at a late stage, in spite of previous experience, leave much to desire. Inadequate follow up care 
in addition to rapidity of growth as good number of studies have suggested a biologically aggressive 
form of breast cancer in Nigerians and other black women32,33. They are usually of poorly 
differentiated invasive ductal carcinoma “Not Otherwise Specified” with high proliferation ratio and 
poor host cellular immune reaction22,34-all translating to poor prognosis. Infiltrating lobular carcinoma 
has been described to have propensity to occur in both breasts24 but none was found in this series, as it 
is uncommon in this environment4. The rarity of carcinoma-in-situ as histology finding in the 
developing world can only be accounted for by non availability of screening facility, in fact greater 
than 90% of most patients after self-detection23. 
 
 




Distinguishing features of primary cancer in contalateral breast has been described to include 
demonstration of in-situ-carcinoma in the breast tissue with invasive carcinoma, histologically 
dissimilar infiltration and location deep within the breast parenchyma35.  
The only case of synchronous bilateral Burkitt’s lymphoma seen died within one year, this is in 
keeping with the experience reported by Aghadiuno et.al36 in which 12 out of 18 patients with 
simultaneous bilateral breast malignancy had Burkitt lymphoma and none survived 2 years. They tend 
to have multi-organ involvement as depicted in a case report by Fadiora et.al.37  
 
Young age, strong family history, histology confirming infiltrating lobular carcinoma, or gross 
multicentricity in the first primary tumour are considered as factors predisposing to developing 
PCBC14,24. Any of these should alert the surgical oncologists on the need for detail follow-up so as to 
be able to diagnose a CBC early enough with the hope of better prognosis. Outcome of treatment for 
patients with breast cancer in the developing world is generally poor.  
Follow-up of patients with unilateral disease should include frequent self breast examination, 3-
monthly clinical breast examination by physician, half yearly or yearly mammography or breast 
magnetic resonance imaging (MRI). MRI is known to detect occult malignancy missed by 
mammography38. 
 
Use of tamoxifen has been found to reduce the incidence of CPBC in women who received the drug 
as adjuvant therapy for the first primary breast cancer by 47% 39 and has been proved to be of value in 
chemoprophylaxis of breast cancer40. Oophorectomy brought about surgically or by irradiation and 
prophylactic contalateral mastectomy may be considered in those with high risk of developing 
CPBC32. In fact the concept of possible bilateralism of breast cancer should be introduced to our 
patients during the first visit after confirmation of a unilateral lesion and adequate education given on 




The incidence of BBC was 4.26%, most were young with no positive family history, 90% were 
premenopausal and histology was IDC (NOS) in 90%of cases. The burden of BBC is enormous on 
both the patients and the involved treatment team. Effort should be put in to determining the risk 
factors to breast cancer and BBC in the black African women. Improve level of awareness of breast 
cancer, provision of screening facilities, coordinated multi-centered research in breast oncology and 
establishment of specialized oncology center will go a long way in improving the outcome of 
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